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Abstract
Mucosal vaccination has been demonstrated to be an effective means of eliciting protective immunity against aerosol
infections of foot and mouth disease virus (FMDV) and various approaches have been used to improve mucosal response to
this pathogen. In this study, cationic PLGA (poly(lactide-co-glycolide)) nano/microparticles were used as an intranasal
delivery vehicle as a means administering FMDV DNA vaccine encoding the FMDV capsid protein and the bovine IL-6 gene
as a means of enhancing mucosal and systemic immune responses in animals. Three eukaryotic expression plasmids with or
without bovine IL-6 gene (pc-P12A3C, pc-IL2AP12A3C and pc-P12AIL3C) were generated. The two latter plasmids were
designed with the IL-6 gene located either before or between the P12A and 3C genes, respectively, as a means of
determining if the location of the IL-6 gene affected capsid assembly and the subsequent immune response. Guinea pigs
and rats were intranasally vaccinated with the respective chitosan-coated PLGA nano/microparticles-loaded FMDV DNA
vaccine formulations. Animals immunized with pc-P12AIL3C (followed by animals vaccinated with pc-P12A3C and pc-
IL2AP12A3C) developed the highest levels of antigen-specific serum IgG and IgA antibody responses and the highest levels
of sIgA (secretory IgA) present in mucosal tissues. However, the highest levels of neutralizing antibodies were generated in
pc-IL2AP12A3C-immunized animals (followed by pc-P12AIL3C- and then in pc-P12A3C-immunized animals). pc-
IL2AP12A3C-immunized animals also developed stronger cell mediated immune responses (followed by pc-P12AIL3C-
and pc-P12A3C-immunized animals) as evidenced by antigen-specific T-cell proliferation and expression levels of IFN-c by
both CD4+ and CD8+ splenic T cells. The percentage of animals protected against FMDV challenge following immunizations
with pc-IL2AP12A3C, pc-P12AIL3C or pc-P12A3C were 3/5, 1/5 and 0/5, respectively. These data suggested that intranasal
delivery of cationic PLGA nano/microparticles loaded with various FMDV DNA vaccine formulations encoding IL-6 as a
molecular adjuvant enhanced protective immunity against FMDV, particularly pc-IL2AP12A3C with IL-6 gene located before
P12A3C gene.
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Introduction
Foot and mouth disease virus (FMDV) infections following
exposure to contaminated aerosols can be prevented by neutral-
izing mucosal immune responses directed against FMDV antigens,
suggesting that vaccines designed to elicit mucosal FMDV-specific
immunity at major mucosal surfaces can interfere with viral
transmission [1]. Since protection against mucosal infection has
been attributed to the production of anti-FMDV-specific IgA
antibodies [2], elicitation of IgA at these surfaces has been deemed
an important parameter in the development of vaccines designed
to elicit protective immune responses against FMDV [3].
Interleukin-6(IL-6) is a multifunctional Th2-associated cytokine
produced by macrophages, dendritic cells, T cells, endothelial cells
and hepatocytes [4] that plays a role in the terminal differentiation
of B cells, proliferation of lymphocytes and endothelial cells,
regulation of IL-2 receptor expression, differentiation of CTL
responses, up-regulation of acute phase proteins, Th2 differenti-
ation (via the upregulation of IL-4 by precursor T helper cells) and
regulation of Th1-associated cytokines [5].
Since DNA plasmid vaccines used to stimulate mucosal
immunity can be easily degraded by DNases present at mucosal
surfaces, DNA plasmids were adsorbed onto chitosan-coated
PLGA particles that were shown to be protected against enzymatic
degradation [6]. For biodegradable and biocompatible character-
istics, poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles have
been extensively utilized in the sustained and targeted delivery of
various agents, including anticancer drugs [7], plasmid DNA [8],
proteins or peptides [9,10] and low-molecular-weight compounds
[11]. PLGA nanoparticles have hence been used to increase the
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27605concentrations of drugs crossing various biological barriers,
including the blood-brain barrier, gastrointestinal and mucosal
surfaces and ocular tissues [12]. Because of its cationic nature,
chitosan has been widely tested as a non-viral gene delivery system
[13]. Its mucoadhesive properties and its ability to modulate tight
junction integrity resulting in increased paracellular transport,
make it an ideal candidate for the delivery of DNA vaccines to
mucosal tissues [14]. Furthermore, chitosan-coated PLGA nano-
particles were found to increase the penetration of the encapsu-
lated macromolecules at mucosal surfaces [12,15].
In this study, using chitosan-coated PLGA nanoparticles as a
delivery vehicle, we sought to explore whether plasmids encoding
FMDV capsid protein and bovine IL-6 as mucosal adjuvant, and
the different position of IL-6 among the plasmids can improve the
stimulation of mucosal and systemic immune responses.
Results
Construction and plasmid characterization
Three plasmids were constructed successfully and confirmed by
PCR, enzyme digestion (Figure 1) and sequence analysis. Plasmid
expression was confirmed using an indirect immunofluorescence
assay (Figure 2). Transfected cells were incubated with anti-FMDV
positive sera followed by an incubation with a fluorescein-
conjugated anti-rabbit IgG. As anticipated, cells transfected with
pA, pB or pC fluoresced compared to the negative controls
(Figure 2).
TEM analysis revealed that cells transfected with plasmid pA
(Figure 2E) and pC (Figure 2F) presented with detectable empty
capsid structures but cells transfected with pB did not, perhaps
because P12A protein encoded by plasmid pB harboured three
additional amino acids after 2A protein self-cleavage between IL-6
and P12A protein, including the amino-terminal proline of 2A
protein, upstream of amino-terminal glycine of P1, according to
reports [16,17]. The absorbance values of cells transfected with
plasmids pA, pB or pC decreased, but the negative control and
irrelevant control absorbance values remained unchanged
(Figure 3A). No significant expression level of FMDV capsid
protein between pA, pB and pC transfected cells was observed
when the cell lysis undiluted.
Characterization of IL-6 production following transfection with
either pB or pC produced significantly higher IL-6 levels than
untransfected controls, suggesting that transfection of BHK-21
cells with pB and pC resulted in significant levels of IL-6
production (Figure 3B). However, there is no significantly
difference for expression level of IL-6 between pB- and pC-
transfected cells. In order to confirm the bovine IL-6 reacting well
on rodents, we had predicted the reactivity of IL-6 between
bovine, rat and human through bioinformatics methods, and
concluded that bovine IL-6 may have a well reactivity on rat [18].
However, the reactivity of bovine IL-6 on guinea pig was not
predicted because the sequence of guinea pig IL-6 is not available
from Genbank.
Characterization of microparticles properties
The particle characterization by the scanning electron micro-
scope shows at (Figure 4). The average diameter of the particles
determined by ZetaSizer Nano ZS before and after freeze-drying
was 462.5 nm and 1975 nm, respectively. The zeta potential of
the particles remained unchanged with 41.3 mV at pH 3.0 before
and after freeze-drying. The particles protected plasmid DNA
from DNase I digestion compared to plasmids that were digested if
they were absorbed with the microparticles (Figure 5), suggesting
that plasmids absorbed on particles could be effectively delivered
to mucosal environments without compromising the integrity of
the DNA.
IL-6 as adjuvant increases the level of serum IgG
Immunized guinea pig serum antibody titers reactive against
FMDV strain Asia I were measured by indirect ELISA. Specific
anti-FMDV antibody responses were assessed at 0, 10, 24 and 38
days after the first immunization. Interestingly, the highest
antibody titers were observed in pC-immunized animals that were
statistically higher than titers observed from animals in other
groups at day 38 after the first immunization (p , 0.05) (Figure 6).
IL-6 enhances mucosal immune responses
On day 35 and 42 days after the first intranasal (i.n.)
immunization, sIgA nasal and vaginal responses specific for
FMDV were assessed by ELISA. Our results demonstrated the
presence of significantly elevated levels of FMDV-specific sIgA
antibodies in vaginal wash samples from guinea pigs vaccinated
with pC compared to animals vaccinated with pA or pB (Figure 7).
The FMDV-specific sIgA antibodies in nasal wash samples shown
similar pattern, but there are no significant differences among
guinea pigs vaccinated with pC, pA and pB (data not shown).
sIgA production at mucosal sites
Levels of expression and sites of sIgA production in the lungs,
tracheas and small intestines of animals in the respective vaccine
groups were assessed by immunohistochemical analysis. The
Figure 1. Restriction pattern profiles of digested plasmids. Plasmid pA (gel on left), pB (middle gel) and pC (gel on right) were enzymatically
digested. Digests were subjected to agarose gel electrophoresis. M, DNA ladder; Lane 1, pcDNA3.1; Lane 2, undigested plasmid; Lane 3, EcoRl
digested plasmid; Lane 4, BamHI and XbaI digested plasmid; Lane 5, PCR product of target gene.
doi:10.1371/journal.pone.0027605.g001
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harvested from animals immunized i.n. with pC, followed by
animals immunized i.n. with pA and then animals immunized i.n.
with pB (Figure 8), paralleling the serum IgA response described
above. The significant IgA expression in the alveoli and the
intestinal villi supported previous observations [19] suggesting that
of the use of DNA encoding IL-6 as a component of the vaccine
stimulated the production of higher sIgA concentrations at
mucosal sites.
Characterization of T-cell responses in vitro
Single cell splenocyte suspensions were prepared from rat
spleens 7 days after the second immunization. Following
stimulation with FMDV, the highest levels of proliferation were
observed in splenocytes harvested from pB-immunized animals
followed by proliferation of cells harvested from pC- or pA-
immunized animals (Figure 9). Proliferation was significantly
higher in cells harvested from animals in all the vaccine groups
compared to the proliferation observed for cells harvested from the
vector control-immunized group.
Effect of IL-6 on T cell cytokine expression profiles
To understand the effect of IL-6 as a mucosal adjuvant,
splenocytes were isolated 7 days after the second immunization
and stimulated with inactivated FMDV in vitro. Cells were then
double-stained with anti-CD4 and anti-IL-4, anti-CD4 and anti-
IFN-c or anti-CD8 and anti-IFN-c and analyzed in FACS. The
highest percentage of antigen-induced IL-4 and IFN-c producing
CD4+ and CD8+ T cells was observed in splenocytes harvested
from the pB-immunized groups followed by splenocytes harvested
from the pC and pA groups, respectively (Figure 10). In addition,
CD4+CD8 +double-positive cells could be induced because CD4+
IFN-c+ cells or CD8+ IFN-c+ cells are much more numerous than
CD4-IFN-c+ cells or CD8-IFN-c+ cells respectively following rats
vaccinated with pA, pB, pC compared to control group (Figure 10).
CD4+CD8+ double-positive cells induced by vaccination were
also reported by [20,21].
The effect of IL-6 on DC maturation
Since IL-6 is an excellent candidate for enhancing innate
immunity against viral infections [22] and DCs play a critical role
in mediating the initiation of cellular immune responses
compatible with viral clearance, the role of IL-6 in mediating
DC maturation was assessed in the respective vaccine groups.
Forty-eight hours post boost immunization, DCs isolated from rats
immunized with pB had the highest expression levels of CD80,
CD86 and MHC-II followed by expression levels of these markers
on DCs harvested from pC- and then pA-immunized rats
(Figure 11). DCs expressing MHC-II shown the similar pattern,
but there are no significant differences among pA-, pB- and pC-
immunized rats (bar graph not shown).
Characterization of neutralizing viral antibodies
Since the level of neutralizing antibodies correlates with
protection against FMDV infections, the anti-viral neutralizing
serum antibody titers from immunized guinea pigs were assessed
(Figure 12). The highest levels of neutralizing antibody titers were
observed in animals immunized with pB followed by titers in the
serum from animals immunized with pC or pA, respectively.
Neutralizing titers from animals in all of the vaccine groups were
Figure 2. Detection of the FMDV structure protein and FMDV capsid. Immunofluoresence was used to determine the expression levels of
the FMDV structure protein following transfection with either pcDNA3.1(+) (a), pA (b) pB (c) or pC (d). FMDV capsid was observed by TEM of BHK-21
cells transfected with pA (e) or pC (d).
doi:10.1371/journal.pone.0027605.g002
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PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27605Figure 3. Characterization of FMDV protein and IL-6 production in BHK-21 cells. (A)Two days after transfection with either pA, pB or pC,
and negative control (PBS) and irrelevant control (Bovine Serum Albumin, BSA) were added; BHK-21 cells were analyzed for expression of FMDV
proteins by sandwich-ELISA. BHK-21 cell lysates were diluted twofold. The data are expressed as the mean OD for each dilution. (B) Expression of IL-6
was determined by assessing IL-6 levels in BHK-21 cell lysates by ELISA two-days after transfection. The data are expressed as the mean OD 6 SEM,
measured in duplicate. Means were compared by non-parametric ANOVA.
doi:10.1371/journal.pone.0027605.g003
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immunized with vector alone.
Protection studies
Guinea pigs in all the vaccination groups (n=5) were
subcutaneously challenged with 0.2 ml 100 TCID50 of live virus
on the left rear foot 2 weeks after the third vaccination. Sixty
percent (3/5) of pB-immunized guinea pigs were protected and
20% (1/5) of pC-immnized guinea pigs were protected from
FMDV challenge (Table 1). Guinea pigs in the remaining vaccine
and control groups developed vesicles in both rear feet 2 days post
challenge. The guinea pigs that did not develop secondary vesicles,
were judged to be completely protected against challenge with
FMDV, suggesting that the pB formulation provided significant
levels of protection.
Discussion
As reported by [23,24], utility of nanoparticles for drug delivery
do not deposit efficiently in the lungs because of exhalation of a
majority of the inhaled dose. Therefore, the nanoparticles-
containing microparticles were formulated through freeze-drying
the nanoparticles with mannitol added in order to embrace the
virtues of both nano- and micro-scale particles, as microparticles
turned into nanoparticles rapidly while the mannitol dissolves into
water in physiological conditions [25]. This strategy is also
regarded as efficient approach to improve the drug absorption
by [25,26].
One question addressed by this study was whether IL-6 is
potential as mucosal adjuvant, therefore, pC was constructed with
IL-6 located between P12A and 3C sequence in contrast to pA
without IL-6 inserted because this strategy is proved to be effective
by [27]. Our study showed that pC vaccination increased the
levels of antigen-specific sIgA (vaginal wash, p,0.05; nasal washes,
p.0.05) that correlated with higher IgA expression levels in the
lungs, trachea and small intestines compared to IgA responses
observed in pA-immunized rats. These higher sIgA levels elicited
Figure 4. SEM analysis of particle morphology. Particles with plasmids before (a) and after (b) freezing-dry. Magnification 20,0006.
doi:10.1371/journal.pone.0027605.g004
Figure 5. Degradation protection assays of particle-loaded
plasmids. Particle-loaded plasmids were incubated with DNaseI. Lane
1, particle loaded plasmid digested with DNase; Lane 2, particle loaded
plasmid in the absence of DNaseI digestion; Lane 3, pure plasmid
digested with DNaseI; Lane 4, undigested plasmid.
doi:10.1371/journal.pone.0027605.g005
Figure 6. Guinea pig anti-FMDV serum antibody responses.
Guinea pigs (n=5) were immunized with three doses of chitosan PLGA-
loaded pA, pB, pC or pc-DNA3.1 at biweekly intervals. Serum samples
were collected on days 0, 10, 24 and 38 after primary immunization and
the IgG response assessed by ELISA. Data are measured in duplicate and
presented as the mean 6 SEM. Means were compared by non-
parametric ANOVA. Significant results between pA-immunized animals
and control groups are indicated by #,Significant results between pC-
and pA-immunized animals are indicated by *, and between pB-
immunized groups are indicated by **.
doi:10.1371/journal.pone.0027605.g006
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specific antibody responses(p,0.05) and stronger FMDV neutral-
izing antibody responses(p.0.05) compared with that following
pA vaccination, suggesting that the presence of IL-6 as a vaccine
component (acting as a cytokine adjuvant) significantly contributed
to the elicitation of mucosal and humoral immune responses.
Besides, pC-immunized animals also developed more potent cell-
mediated responses, evidenced by the higher percentage of IL-4
(p,0.05) and IFN-c (p,0.05) producing CD4+ cells and IFN-c
producing CD8+ T cells (p.0.05) and DCs that possessed higher
CD80 (p,0.05), CD86 (p.0.05) and MHC II (p.0.05)
expression levels compared to pA-immunized rats. In addition,
one out of five guinea pigs vaccinated with pC was protected
against FMDV challenge, in contrast to none of guinea pigs
vaccinated with pA protected. These data suggested that
incorporation of IL-6 as part of the FMDV DNA vaccine
enhanced mucosal and systemic immune responses specific to
FMDV.
Another question addressed by this study was whether targeting
FMDV capsid protein to endoplasmic reticulum (ER) can improve
the immune responses. Through the signal peptide of IL-6 at the
N-terminus, the FMDV capsid protein produced by pB can be
targeted to ER but that produced by pC can not according to
report [28]. Our results shown that pB vaccination resulted in
higher levels of neutralizing antibody titers (p,0.05), a higher
percentage of cells responding to antigen stimulation measured by
IL-4 (p,0.05) and IFN-c (p.0.05) production by CD4+ T cells
and IFN-c (p.0.05) production by CD8+ T cells, higher CD80,
CD86 and MHC II expression levels from DCs (p.0.05)
compared to similar responses from pC-immunized animals.
And pB i.n.-immunized animals had the highest protection rate
(3/5) compared with (1/5) of pC i.n.-immunized animals.
Consistent with our results, animals vaccinated with plasmid
DNA encoding VP1 protein of FMDV [29], outer surface protein
C of Borrelia burgdorferi [30], HBsAg [31], fragment C of tetanus
toxin [32], ovalbumin [33] and gp120 protein of HIV-1 [34] fused
to the ER-targeting secretory signal peptide induced stronger
immune response compared to that of animals vaccinated with
similar antigen without ER-targeting secretory signal peptide
fused. Secretion of VP1 [29] and P1 [35] protein of FMDV from
cells transfected with plasmid DNA encoding VP1 and P1 fused
with ER-targeting secretory signal peptide were reported,
therefore, it is tempting to speculate that the FMDV capsid
protein could also be secreted from cells transfected with pB but
not pC. An attempt to observe whether there are significant
differences of FMDV capsid protein levels in culture supernatant
of BHK-21 cells transfected with pB and pC was made without
success because of severe cellular death (data now shown). It is
reported that 3C protein of FMDV could lead to the change in cell
morphology closely mimicking FMDV infection leading to
cytopathic effect in vitro [36], but there is no report for cellular
death in vivo due to 3C protein. Taken together, we speculated the
possible mechanism of improving immune responses through ER-
targeting strategy could lies in that secreted FMDV capsid proteins
are more efficient in presenting for B cells and antigen presenting
cells than cytoplasmic FMDV capsid protein.
Interestingly, our results showed that pB vaccination resulted in
lower FMDV-specific antibody IgG (p,0.05), IgA (p,0.05) titers
(vaginal wash) and obvious lower IgA expression levels in the
lungs, trachea and small intestines compared to similar responses
from pC-immunized animals, which is inconsistent with neutral-
izing antibody responses. Similar results have been reported
previously. For example, the ratio of neutralizing antibody
induced by inactivated FMD vaccine containing 146S antigen at
14 and 28 days post first vaccination is 1.41 and 1.45 respectively,
however, the ratio of specific antibody induced by inactivated
FMD vaccine and empty capsid-like particles at 14 and 28 days
post first vaccination are both much higher than 2 [37]. There is
Figure 7. Characterization of FMDV-specific sIgA responses. sIgA FMDV-specific responses were assessed vaginal washes by ELISA. Guinea
pigs (n=5) were vaccinated i.n. with the respective vaccine formulations on days 0, 14 and 28. Vaginal washes were collected on days 35 and 42. Data
are measured in duplicate and presented as the mean 6 SEM. Means were compared by non-parametric ANOVA. Significant results between pA-
immunized animals and control groups are indicated by #, significant results between pC- and pA-immunized animals are indicated by *, and
between pB-immunized groups are indicated by **.
doi:10.1371/journal.pone.0027605.g007
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27605Figure 8. Histologic characterization of sIgA production in tracheas, lungs and small intestines of immunized rats (n=3). Sections
from the respective tissues were obtained from rats that were intranasally vaccinated. Sections were analyzed by immunohistochemistry following
incubation with a labeled anti-IgA antibody. Detection of sIgA in respective samples was examined under light microscopy at 406magnification.
Brown staining is representative of sIgA-positive cells from tracheas (A–D), lungs (E–H) and small intestines (I–L). Sections A, E and I were taken from
unimmunized animals; sections B, F and J represent tissues harvested from rats immunized intranasally with pA; sections C, G and K represent
sections from rats intranasally vaccinated with pB and sections D, H and L represent rats intranasally vaccinated with pC.
doi:10.1371/journal.pone.0027605.g008
Figure 9. Lymphocyte proliferation. Single lymphocyte suspensions were isolated from rats (n=6) 7 days after the second immunization, plated
in triplicate in a 96-well plate and stimulated in vitro for 48 h with inactivated FMDV, Con A (positive control) or with BSA. Means were compared by
non-parametric ANOVA. Proliferation was analyzed using the MTT colorimetric assay and proliferation expressed as stimulated index. Significant
results between pA-immunized animals and control groups are indicated by #.
doi:10.1371/journal.pone.0027605.g009
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inactivated enterovirus 71 antigen and VP1 protein from
enterovirus 71, while specific antibody titers induced by inactivat-
ed enterovirus 71 are significantly higher than those induced by
VP1 [38]. In addition, there are data showing that unmyristoy-
lated FMDV capsid protein can assembly into 17S particles and
react with monoclonal antibodies against mature virus [39]. Thus,
we speculate that the rapid degradation of un-assembled FMDV
capsid protein may lead to insufficient amounts of native protein
required to induce a strong FMDV specific antibody response.
However, further tests on the efficiency of the 17S capsid protein
to induce immune responses compared with 146S or 75S capsid
protein should be performed in future.
In summary, IL-6 effectively functioned as a mucosal adjuvant
capable of significantly enhancing mucosal and systemic immune
responses especially humoral immune responses. Furthermore,
pB-immunized animals developed a significantly stronger immune
response and provided better protection than animals immunized
with the pC formulation, suggesting that differences in FMDV
protein (and IL-6) targeting to the ER differed between DNA
vaccine formulations. These studies demonstrated that an i.n.
immunization strategy comprised of the pB formulation could be
developed as an FMDV mucosal vaccine for use in animals
following additional testing in protection-challenge experiments
and using an animal model that can test the efficacy of these
formulations following i.n. challenge.
Materials and Methods
Animals
Wistar rats (Lanzhou University, Lanzhou, China) weighing at
200–250 g and guinea pigs (Lanzhou veterinary research institute,
China) weighing at 250–300 g were maintained under pathogen-
free conditions with free access to pathogen-free food and water.
The animal experiments were approved by Gansu Provincial
Science and Technology department in China and conducted
accordingly. Experiments conformed to the local (Regulations for
the administration of affairs concerning experimental animals) and
international (Dolan K. 2007 Second Edition of Laboratory
Animal Law. Blackwell, UK) guidelines on the ethical use of
animals.
Plasmids
The pcDNA3.1(+) plasmid was purchased from Invitrogen
(Carlsbad, CA) and the pMD18-T plasmid purchased from
TaKaRa Co. Ltd (Shiga, Japan). Large-scale plasmid preparations
were carried out by alkaline lysis using Endofree Qiagen Plasmid-
Giga kits (Qiagen, Valencia, CA) according to the manufacturer’s
instructions.
Antibodies and fluorescent dye
Fluorescent-conjugated anti-rat monoclonal anti-IL-4-PE, anti-
IFN-c-FITC, anti-CD4-PE, anti-CD4-FITC, anti-CD8-PE and
the respective isotype controls were purchased from BD
PharMingen (San Diego, CA). Anti-CD11c-FITC, anti-CD80-
PE, anti-CD86-PE and anti-MHC-II-PE were purchased from
eBioscience (San Diego, CA).
Construction of the FMDV DNA vaccine
The FMDV Asia/HeB P12A3C gene fragment was amplified
from the pMD-P12A3C plasmid encoding capsid polypeptide
(P12A) and 3C protease of FMDV maintained in our laboratory.
The bovine IL-6 gene was cloned and inserted into pMD18-T
simple vector (TaKaRa Co. Ltd.) as described in Figure 13.
Transfections
Baby hamster kidney (BHK-21) cells (Boster, Wuhan, China)
(4610
5) were seeded onto cover slips on six-well plates and
incubated at 37uCi naC O 2 incubator until the cells were 80%
confluent. The following day, 10 mg of plasmid DNA in 100 mlo f
minimal essential media (MEM) with reduced serum (Thermo
Fisher, Waltham, MA) was mixed with 6 ml of Lipofectamine
TM
(Invitrogen). The mixture was then incubated at 20uC for 30 min
before adding an additional 800 ml reduced-serum MEM that was
then added to the cells. After incubation for 5 h at 37uCi na
humidified CO2 incubator, 1 ml of medium containing 5% fetal
calf serum was added to each well.
Two days after transfections, cells were analyzed for expression
of FMDV and IL-6 by the indirect immunofluorescence test
(IFAT) and sandwich-ELISA (enzyme-linked immunosorbent
assay) [40,41,42].
For IFAT, cell monolayers were cultured on coverslips and fixed
in cold acetone (220uC for 30 min). Samples were incubated with
rabbit anti-FMDV serum (1:1000 at 37uC for 30 min) in a
humidified chamber and then stained with FITC-conjugated goat
anti-rabbit serum (1:200) for 1 h at 37uC and then observed
microscopically.
For sandwich ELISAs designed to detect FMDV protein, cells
were washed 48 h after transfection, scraped from the wells and
then lysed with lysis buffer (Sangon, Shanghai,China). The lysate
was normalized to the total protein content. The lysate was diluted
1:2 with PBS and added to 96-well flat-bottomed plates (Nunc,
Rochester, NY) coated with rabbit anti-FMDV serum overnight at
4uC as above. Subsequently, plates were washed thoroughly with
PBST (phosphate buffer saline with 1% tween 20) and anti-FMDV
guinea pig sera added to each well. The plates were incubated for
60 min at 37uC and peroxidase-conjugated rabbit anti-guinea pig
IgG (Sigma) at a 1:2000 dilution was added for 1 h at 37uC
followed by the addition of OPD-H2O2. Absorbance was
measured at 492 nm 15 minutes later.
Lysed cells normalized to the total protein content were added
to 96-well flat-bottom plates and detection of IL-6 by ELISA
carried out as described by the bovine IL-6 kit instruction (Thermo
Fisher) just expressing the IL-6 titer from transfected cells in
optical density (OD).
Preparation of plasmid DNA (pDNA)-adsorbed CHT-PLGA
Nanoparticles were prepared using the emulsion-diffusion-
evaporation technique [43]. Briefly, 200 mg of PLGA (50 kDa)
(Shandong institute of medical instruments, China) were dissolved
Figure 10. Analysis of cytokine production resulting from antigen-specific stimulation. T cells isolated and purified from the spleens of
rats (n=3) following the second immunization with respective FMDV DNA vaccines were stimulated with inactivated FMDV for 6 h in vitro and
analyzed by FACS. The percentage of positive cells is shown in each dot-plot in the upper right corner. Data are a representative from three
independent experiments. Data are presented as the mean 6 SEM. Means were compared by non-parametric ANOVA. Significant results between
pA-immunized animals and control groups are indicated by #, significant results between pC- and pA-immunized animals are indicated by *, and
between pB-immunized groups are indicated by **.
doi:10.1371/journal.pone.0027605.g010
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PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e27605Figure 11. Analysis of DC maturation by FACS. Rat (n=3) splenocytes were isolated after the second immunization with the respective FMDV
DNA vaccine formulations. Harvested cells were double-stained for CD80 and CD11c, CD86 and CD11c. The percentage of double-positive cells in the
dot-plot is shown in upper right corner and the gate was set on the CD11c+ cells or events. Data are a representative from three independent
experiments. Data are presented as the mean 6 SEM. Means were compared by non-parametric ANOVA. Significant results between pA-immunized
animals and control groups are indicated by #, significant results between pC- and pA-immunized animals are indicated by *.
doi:10.1371/journal.pone.0027605.g011
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was added to an aqueous stabilizer mixture containing 100 mg of
Poly(vinyl alcohol) (PVA) (Sigma)and 30 mg of chitosan (75% to
85% deacetylated, 50–190 kDa) (Sigma) in 10 ml water under
stirring. The emulsion was stirred at room temperature for 3 h
before homogenizing at 2 000 g (13500 rpm) for 10 min using an
Ultra-Turrax T18 homogenizer (Janke and Kunkel GmbH KG,
Staufen, Germany). To this emulsion, water was added under
stirring, resulting in nano-precipitation. Stirring was continued in
a water bath maintained at 40uC for 24 h to remove organic
solvents and the solution was then concentrated and resuspended
three times to remove residual PVA. CHT-PLGA nanoparticles
were stored at 4uC.
pDNA-loaded CHT-PLGA nanoparticles were prepared by
mixing the nanoparticles and plasmid (ratio of particles to plasmid
was 120:1(w/w)) at a nanoparticle concentration of 4 mg/ml in
MilliQ-water (pH5). Complex formation were performed at room
temperature and allowed to stand for 10 h to allow complexes to
form. pDNA-loaded CHT-PLGA nanoparticles were stored at
4uC.
The sample made above was prepared for freeze-drying. The
nanoparticles and enough mannitol were added to empty, clean
borosilicate vials to achieve a 1:2 mannitol-to-nanoparticles ratio.
The appropriate volume of purified particle solution was added to
the vial and mixed gently until mannitol was dissolved. The
sample was allowed to freeze-dry at 240uC for 48 hours (Hitachi
Ltd, Japan), followed by a second drying cycle at a temperature of
20uC for about 8 h. The obtained powder was stored under
refrigerated conditions until further use.
Characterization of nano/microparticle properties
Particle characteristics were determined before and after freeze-
drying. Particles were characterized with respect to size and
surface charge by measuring the zeta potential using a ZetaSizer
Nano ZS (Malvern Instruments Ltd., Worcestershire, UK).
Measurements were based on photon correlation spectroscopy at
25uC and a 90 degree scattering angle. All measurements were
performed in triplicate at 25uC using the standard settings for
water as the dispersion medium.
Nanoparticles with plasmid were deposited on glass, dried for
15 min and then sprinkled with gold powder. The characteristics
of the chitosan–plasmid complex surface were then observed using
Field Emission-scanning electron microscope (Jeol Ltd., Tokyo,
Japan).
Nanoparticle-DNA complexes were prepared by mixing
nanoparticles with plasmid at a concentration of 10 mg/ml in
MilliQ-water. Complex formation studies were performed at room
Figure 12. Characterization of FMDV-specific neutralizing antibodies. Serum samples were harvested from guinea pigs (n=5) on day 38
after the first immunization. Dots represent the level of neutralizing antibodies from each individual animal. Horizontal bars represent the mean
neutralizing antibody levels from respective groups. Means were compared by non-parametric ANOVA. Significant results between pA-immunized
animals and control groups are indicated by #, significant results between pC- and pB-immunized animals are indicated by **. The results are
presented as the mean 6 SEM of neutralizing antibody titer.
doi:10.1371/journal.pone.0027605.g012







A pc-P12A3C 0/5 5/5 5/5
B pc-IL2AP12A3C 3/5 5/5 2/5
C pc-P12AIL3C 1/5 5/5 4/5
D pcDNA 0/5 5/5 5/5
E PLGA 0/5 5/5 5/5
Severity of symptoms was based on daily monitoring until 7 days post
challenge.
aGuinea pigs were challenged 31 days post vaccination.
bNumber of animals without signs of disease/total.
cNumber of animals with signs of disease/total.
doi:10.1371/journal.pone.0027605.t001
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formation. Nanoparticle-DNA complexes were incubated with
100 units of DNase I at 37uC in 100 ml reaction buffer (40 mM
Tris–HCl, pH 7.5, 8 mM MgCl2, and 5 mM DTT) for 20 min
and stopped by 50 ml stop solution (100 mM EDTA, pH 8.0). The
same conditions without nanoparticle-DNA complexes were used
in the control experiments. The nanoparticle-DNA complexes
were electrophored on agarose gels for 30 min at 5 V/cm. Images
were acquired using a Geldoc 2000 gel documentation system
(Bio-Rad, Munich, Germany) equipped with a UV translumina-
tor.
Immunization procedures
Rats were randomly divided into 5 groups (n=6) and guinea
pigs randomly divided into 5 groups (n=5). Animals were
immunized i.n. with either PLGA, pcDNA3.1, pA: pc-P12A3C,
pB: pc-IL2AP12A3C or pC: pc-P12AIL3C on days 0, 14 and 28
(Table 2). Female guinea pigs and rats were vaccinated i.n. with 3
or 2 times administrations of vaccine at 200 mg plasmid (36 mg in
powder) respectively. Female rats were fully anesthetized by
intraperitoneal injection of ketamine before immunization. A
MicroSprayer (PennCentury, Philadelphia, PA) was used for i.n.
liquid delivery. Animals immunized with chitosan-PLGA only
were used as negative controls.
Assessment of humoral responses
ELISAs were used to detect antibody levels against FMDV in
sera, vaginal and nasal washes of immunized rats. Vaginal and
nasal wash samples were collected by washing the vaginal and
nasal cavities of guinea pigs with 100 ml of sterile PBS respectively.
Ninety-six-well microtiter plates were coated with inactivated
FMDV (100 ml/well) in 0.05 M bicarbonate buffer (pH 9.6) at
4uC overnight. Wells were then blocked with 0.1% of FBS (fetal
bovine serum) in 3% BSA (bovine serum albumin)–PBST at 37uC
for 1 h, washed and a 1:50 dilution of guinea pigs serum or a 1:30
dilution of vaginal or nasal washes were added to respective wells.
A secondary antibody, horseradish peroxidase-labeled goat anti-
guinea pig IgG (Genetex, San Antonio, TX) or horseradish
peroxidase-conjugated goat anti-guinea pig IgA (ICL, Inc.,
Oregon, OR), were diluted 1:1000 and added into each well
and incubated at 37uC for 1 h. TMB tablets (10 mg) (Sigma) were
dissolved in 0.025 M phosphate–citrate buffer and added to each
well (100 ml), color development stopped by adding 2 M of H2SO4
after 15 minutes and absorbance determined at 450 nm using a
plate reader (BioTek, Vermont, USA). Antibody reactivity was
reported as OD values.
Immunohistochemical analysis
Trachea, lung and small intestine samples were isolated from
immunized rats and fixed using 4% paraformaldehyde, 0.1%
glutaraldehyde and 0.2% picric acid in 0.1 M PBS (pH 7.2) at room
temperature for 48 h. Serial tissue sections (5 mm thickness) were
obtained after the tissues were embedded in paraffin. Antigen detection
was performed by heating the sections for 10 min at 120uCi n0 . 1M
sodium citrate buffer (pH 6.0). Subsequent steps were performed as the
Figure 13. Schematic representation describing the construction of pA, pB and pC.
doi:10.1371/journal.pone.0027605.g013
Table 2. Immunization groups.
Groups Animals Number Vaccine
a Adjuvant
A Rat 6 pc-P12A3C Chitosan-PLGA
B Rat 6 pc-IL2AP12A3C Chitosan-PLGA
C Rat 6 pc-P12AIL3C Chitosan-PLGA
D Rat 6 pcDNA3.1 Chitosan-PLGA
E Rat 6 None Chitosan-PLGA
A Guinea pig 5 pc-P12A3C Chitosan-PLGA
B Guinea pig 5 pc-IL2AP12A3C Chitosan-PLGA
C Guinea pig 5 pc-P12AIL3C Chitosan-PLGA
D Guinea pig 5 pcDNA3.1 Chitosan-PLGA
E Guinea pig 5 None Chitosan-PLGA
aPlasmids were purified and formulated in PBS at 1 mg/ml. Guinea pigs and rats
were vaccinated intranasally 3 or 2 times respectively.
doi:10.1371/journal.pone.0027605.t002
Developing Mucosal Vaccine against FMDV
PLoS ONE | www.plosone.org 12 November 2011 | Volume 6 | Issue 11 | e27605instruction of Cell and Tissue Staining Kit-Goat Kit (R&D Systems
Inc., Minneapolis, US), and goat anti-rat IgA (Novus Biologicals,
Littleton, CO) was used as the first antibody. .Positive cells were
visualized under a light microscope at 406.
T cell proliferation
Six rats from each immunization group (and controls) were
sacrificed and single lymphocyte suspensions were prepared from
their spleens 7 days after the second immunization as described
previously [42,43]. Cells were incubated in triplicate in 96-well
plates at 5610
4 cells/well in RPMI-1640 plus 5% fetal calf serum
(FCS) at 37uC in a 5% CO2 incubator. The cells were stimulated
for 24 h with 10 mg/ml Con A (positive control), 10 mg/ml
inactivated FMDV, 5 mg/ml BSA (nonspecific antigen control) or
unstimulated (negative control), respectively. T cell proliferation
was evaluated using a Cell Titer 96 aqueous non-radioactive cell
proliferation assay according to the manufacturer’s instruction
(Promega, Madison, WI). MTT solution (Promega) was added to
each well (20 ml each well). Proliferating cells convert MTT to
formazan salt that can be detected after 4 h incubation. Formazan
formation correlates with cell growth and can be measured by
determining the OD at 595 nm using a plate reader as described
above. Data are expressed as stimulation index (SI), calculated as
the mean reading of triplicate wells of antigen-stimulated cells
divided by the mean reading of triplicate wells from unstimulated
(negative control) wells.
Intracellular cytokine staining
Three rats from each immunization group were sacrificed 7
days after the second immunization. Single-cell splenic suspensions
(5610
5 cells/200 ml) were stimulated in 96-well plates with
inactivated FMDV (5 mg/ml) and anti-CD28 (eBioscience, San
Diego, CA) (5 mg/ml) mAb for 12 h at 37uCi n5 %C O 2, followed
by the addition of the monensin (BD PharMingen, San Diego, CA)
(2 mg/ml) for 4 h and then washed twice with PBS. Cells were
blocked with 1 mlo fF c c mAb (Abcam, Cambridge, UK) (0.5 mg/
ml) for 30 min at 4uC and fixed with 4% paraformaldehyde at 4uC
for 15 min before permeabilization with 0.1% saponin (Sigma) at
4uC for 10 min. After rinsed once with PBS, the cells were
incubated with anti-CD4-FITC and anti-IL-4-PE, or anti-CD8-
PE and anti-IFN-c-FITC, or anti-CD4-PE and anti-IFN-c-FITC
(or with the corresponding isotype controls) for 30 min at 4uC.
The fluorescense intensities were measured using a FACS Calibur
flow cytometry and the data analyzed using Cell Questpro
Software (BD Biosciences, San Jose, CA).
DC cell surface co-stimulatory molecules staining
Three rats of each group were sacrificed 7 days after the second
immunization, single-cell suspensions (1610
6 cells/200 ml) from
the spleens were blocked with 2 mlo fF c c mAb (0.5 mg/ml) for
30 min at 4uC. After one PBS wash, cells were used to stain with
isotype controls, or double staining with anti-CD11c-FITC and
anti-CD80-PE, or anti-CD11c-FITC and anti-CD86-PE, or anti-
CD11c-FITC and anti-MHC-II-PE. The fluorescense intensities
were measured using a FACS Calibur flow cytometry and the data
analyzed using Cell Questpro Software (BD Biosciences, San Jose,
CA).
Detection of specific neutralizing antibodies against
FMDV
Serum samples taken from guinea pigs on 38 days after first
immunization were analyzed for neutralizing antibody titers using
a neutralization assay with monolayers of BHK-21 cells [44].
Doubling dilutions of serum samples were reacted with 100
TCID50 of FMDV Asia/HeB at 37uC for 1 h. Cells were then
added as indicators of residual infectivity. Endpoint titers were
determined after 72 h incubation at 37uC and were calculated as
the reciprocal of the final serum dilution that resulted in the
neutralization of the virus activity by 50% (ND50). Titers are
expressed as the reciprocal of this serum dilution step.
Animal infections
Thirty-eight days after primary immunization, guinea pigs were
challenged subcutaneously and intradermally in one of rear leg
with 0.2 ml 100ID50 of FMDV (Asia I strain) and examined for
protection against FMD over the following 7 days. Guinea pigs
that showed FMD-compatible lesions only at the original injection
site were judged to be protected, and those that showed any FMD
clinical signs in the other three feet were judged to be unprotected
[45].
Statistic analysis
The data were analyzed to express the mean 6 standard errors
of the mean (SEM). Differences were considered to be statistically
significant at p,0.05.
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